# TYRA-300

Source: https://onco.cc/drugs/tyra-300/  
OnCo record `tyra-300` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TYRA-300 is an experimental small-molecule drug from Tyra Biosciences in phase 2 trials for bladder & urothelial cancer, aimed at FGFR2.

## Summary

TYRA-300 is a small-molecule drug developed by Tyra Biosciences. Its target is FGFR2 (the sponsor names FGFR3). The sponsor states: TYRA-300 is an oral, FGFR3-selective tyrosine kinase inhibitor that targets tumours containing activating FGFR3 gene alterations. ClinicalTrials.gov describes the intervention as: TYRA-300 is an oral, novel potent FGFR 3-selective tyrosine kinase inhibitor that targets tumours that contain activating gene alterations of FGFR3. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in bladder & urothelial cancer. The largest, NCT05544552, plans to enrol 310 participants with primary completion expected 2026-11. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule
- Mechanism: TYRA-300 is an oral, FGFR3-selective tyrosine kinase inhibitor that targets tumours containing activating FGFR3 gene alterations.

## Sources

- ClinicalTrials.gov: trials of TYRA-300: https://clinicaltrials.gov/search?intr=TYRA-300

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- targets: [FGFR2](https://onco.cc/targets/fgfr2/)
- companies: [Tyra Biosciences](https://onco.cc/companies/tyra-biosciences/)
- trials: [Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer](https://onco.cc/trials/nct06995677/), [Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations](https://onco.cc/trials/nct05544552/)

---
JSON: https://onco.cc/api/v1/entities/tyra-300.json